Immunic CEO Discusses Key 2025 Highlights and 2026 Milestones for Vidofludimus Calcium in Multiple Sclerosis Treatment.

Immunic CEO Daniel Vitt highlighted the phase 2 CALLIPER study's results, showing a 31% reduction in disability worsening in primary progressive MS patients, and consistent long-term results from the EMPhASIS study. The company strengthened its patent position for vidofludimus calcium, with potential exclusivity to 2041, and expects top-line data from the phase 3 ENSURE trials by the end of 2026. Early findings on IMU-856 suggest gut health benefits and potential links to weight management.